Trovafloxacin

Revision as of 19:08, 27 September 2011 by WikiBot (talk | contribs) (Protected "Trovafloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Trovafloxacin
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H15F3N4O3
Molar mass416.353 g/mol

WikiDoc Resources for Trovafloxacin

Articles

Most recent articles on Trovafloxacin

Most cited articles on Trovafloxacin

Review articles on Trovafloxacin

Articles on Trovafloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Trovafloxacin

Images of Trovafloxacin

Photos of Trovafloxacin

Podcasts & MP3s on Trovafloxacin

Videos on Trovafloxacin

Evidence Based Medicine

Cochrane Collaboration on Trovafloxacin

Bandolier on Trovafloxacin

TRIP on Trovafloxacin

Clinical Trials

Ongoing Trials on Trovafloxacin at Clinical Trials.gov

Trial results on Trovafloxacin

Clinical Trials on Trovafloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Trovafloxacin

NICE Guidance on Trovafloxacin

NHS PRODIGY Guidance

FDA on Trovafloxacin

CDC on Trovafloxacin

Books

Books on Trovafloxacin

News

Trovafloxacin in the news

Be alerted to news on Trovafloxacin

News trends on Trovafloxacin

Commentary

Blogs on Trovafloxacin

Definitions

Definitions of Trovafloxacin

Patient Resources / Community

Patient resources on Trovafloxacin

Discussion groups on Trovafloxacin

Patient Handouts on Trovafloxacin

Directions to Hospitals Treating Trovafloxacin

Risk calculators and risk factors for Trovafloxacin

Healthcare Provider Resources

Symptoms of Trovafloxacin

Causes & Risk Factors for Trovafloxacin

Diagnostic studies for Trovafloxacin

Treatment of Trovafloxacin

Continuing Medical Education (CME)

CME Programs on Trovafloxacin

International

Trovafloxacin en Espanol

Trovafloxacin en Francais

Business

Trovafloxacin in the Marketplace

Patents on Trovafloxacin

Experimental / Informatics

List of terms related to Trovafloxacin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Trovafloxacin (sold as Trovan® by Pfizer) is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV [2]. It was withdrawn from the market due to the risk of hepatotoxicity. It had better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones.

Controversy

In 1996, during a meningitis epidemic in Kano, Nigeria, the then-untested drug was administered to approximately 100 infected children. A panel of medical experts later implicated Pfizer in the incident, concluding the drug had been administered as part of an illegal clinical trial without authorization from the Nigerian government or consent from the children's parents.[1] The case came to light in December 2000 as the result of an investigation by The Washington Post, and sparked significant public outcry. The Nigerian federal government has subsequently sued the drug giant for $8.5bn and Pfizer will face criminal and civil charges brought by the state and federal governments of Nigeria.

When it went on the market in 1998 Trovan became one of Pfizer's top-selling drugs. When first-quarter earnings were announced in April of that year, the company's earnings had increased by 15% over the previous year, with analysts attributing much of that increase to the sales of the "new antibiotic" Trovan.[2] Pfizer had spent hundreds of millions of dollars developing Trovan. In the first year it brought over US$160 million and investors expected it to eventually bring in US$1 billion per year.[3]

In June 1999 the U.S. Food and Drug Administration advised doctors to limit the prescription of Trovan after it had been found "strongly associated" with 14 cases of acute liver failure and six deaths. The FDA had received over 100 reports of liver problems in people taking Trovan, which was at that time being prescribed at a rate of 300,000 patients per month in the United States. Two days later the Committee for Proprietary Medicinal Products recommended to the European Commission that marketing approval of Trovan be suspended for a year.[3][4] Between 2002 and 2005 the victims of the Trovan tests in Nigeria filed a series of unsuccessful lawsuits in the United States.

References

  1. Stephens, Joe (May 7, 2006). "Panel Faults Pfizer in '96 Clinical Trial In Nigeria". The Washington Post. p. A01. Retrieved 2006-08-28.
  2. Bloomberg News (April 15, 1998). "2 Drug Companies Report Big Quarterly Profit Gains". The New York Times. p. D.5. ISSN 03624331. |access-date= requires |url= (help) (via ProQuest, Document ID 28630468)
  3. 3.0 3.1 Petersen, Melody (August 27, 2000). "Unforeseen Side Effects Ruined One Blockbuster". The New York Times. p. 3.11. |access-date= requires |url= (help) (via ProQuest, Document ID 58860021)
  4. Reuters (June 12, 1999). "Suspension of Trovan Drug in Europe Is Urged". The New York Times. p. C.3. |access-date= requires |url= (help) (via ProQuest, Document ID 42327418)

Template:QuinoloneAntiBiotics

Template:SIB

th:โทรวาฟลอกซาซิน

Template:WH Template:WS